Filtered By:
Condition: Atrial Fibrillation
Drug: Pradaxa
Countries: China Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 9 results found since Jan 2013.

Cost-effectiveness of dabigatran compared with rivaroxaban for prevention of stroke and systemic embolism in patients with atrial fibrillation in China.
Abstract PURPOSE: In China, dabigatran and rivaroxaban are the only approved non-vitamin K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this article was to assess the cost-effectiveness of dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in Chinese patients with AF from the perspective of the Chinese health care system. METHODS: A Markov model was constructed to estimate the cost-effectiveness of dabigatran versus rivaroxaban. Clinical events were modeled for a lifetime horizon, based on clinical efficacy data from indirect treatment...
Source: Clinical Therapeutics - January 9, 2020 Category: Drugs & Pharmacology Authors: Dong SJ, Wu B, Zhai SD, Zhang YJ, Chu YB, Gupta P, Li YH Tags: Clin Ther Source Type: research

Cost ‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
To evaluate the cost-effectiveness of new anticoagulants and warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF).
Source: BMC Health Services Research - January 28, 2021 Category: General Medicine Authors: Hongtao Wei, Can Cui, Xiangli Cui, Yi Liu and Dandan Li Tags: Research article Source Type: research

A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore
CONCLUSION: NOACs were associated with similar stroke and major bleeding rates as warfarin for NVAF.PMID:33381777 | DOI:10.47102/annals-acadmedsg.2020184
Source: Ann Acad Med Singapo... - December 31, 2020 Category: General Medicine Authors: Wen Jun Tiew Vivien Lx Wong Vern Hsen Tan Yong Chuan Tan Elena Ms Lee Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Persistence, effectiveness and safety of dabigatran in “real-world” Chinese patients with nonvalvular atrial fibrillation
In conclusion, it is of importance for Chinese clinicians to know about these information because dabigatran is a relatively new drug in China. Compared with other reported data, patients of this study have (1) lower dabigatran persistence and lower incident rates of all-cause death, systemic embolism, minor bleeding events and gastrointestinal hemorrhage and (2) higher incident rates of ischemic stroke and intracranial hemorrhage.
Source: Heart and Vessels - January 30, 2020 Category: Cardiology Source Type: research

Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device
CONCLUSION: The safety and efficacy of low-dose dabigatran and rivaroxaban were comparable to those of warfarin within 45 days after Watchman device implantation in a Chinese population.PMID:34740490 | DOI:10.1016/j.jfma.2021.10.015
Source: J Formos Med Assoc - November 6, 2021 Category: General Medicine Authors: Guohua Fu Binhao Wang Bin He Yibo Yu Zhao Wang Mingjun Feng Jing Liu Xianfeng Du Weidong Zhuo Huimin Chu Source Type: research

Pharmacokinetics and Safety of Dabigatran Etexilate after Single and Multiple Oral Doses in Healthy Chinese Subjects
ConclusionsThis study revealed the pharmacokinetic characteristics and good safety profile of dabigatran in healthy Chinese subjects.
Source: European Journal of Drug Metabolism and Pharmacokinetics - May 29, 2020 Category: Drugs & Pharmacology Source Type: research